Document is current
Any future updates will be listed below
-
Authors
Campillo-Davo, Diana
Flumens, Donovan
Berneman, Zwi N.
Fujiki, Fumihiro
Roex, Gils
Versteven, Maarten
Van Acker, Heleen H.
Van Tendeloo, Viggo F. I.
Sugiyama, Haruo
Anguille, Sébastien
Lion, Eva
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G053518N)
Fonds Wetenschappelijk Onderzoek (1S72821N)
Fonds Wetenschappelijk Onderzoek (1S24517N)
Bijzonder Onderzoeksfonds UAntwerpen
UZA foundation
Baillet Latour Fund
Kom op tegen Kanker
Stichting Tegen Kanker (FAF-C/2016/764)
Kaushik Bhansali Fund
Supply Hope Fund for Cancer Immunotherapy
Antwerp International School Scientific Fund for Research in Clinical Hematology
Fischler-Schraub Fund
Methusalem financing program
MeToYou
- License Information
-
More Information
Article History
Received: 18 December 2025
Accepted: 4 March 2026
First Online: 19 March 2026
Declarations
:
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. VFIVT and ZNB are coinventors of a now-elapsed patent covering the messenger RNA electroporation technique (Improved Transfection of Eukaryotic Cells with Linear Polynucleotides by Electroporation, WO/2003/000907). ZNB was a consultant for BioNTech.
